ZIM
INDV icon

Zacks Investment Management’s Indivior Pharmaceuticals INDV Stock Holding History

Zacks Investment Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$594K Buy
14,483
+6,602
+84% +$239K ﹤0.01% 490
2026
Q1 		$240K Buy
+7,881
New +$260K ﹤0.01% 629

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's INDV Position: Q2 2026 in Review

Zacks Investment Management increased its Indivior Pharmaceuticals (INDV) stake by 84% in Q2 2026, buying an estimated $239K and bringing the position to 14,483 shares worth $594K. The position accounts for ﹤0.01% of the portfolio, ranked #490.

Zacks Investment Management first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Zacks Investment Management held 14,483 shares of Indivior Pharmaceuticals worth $594K as of Q2 2026.
  • Zacks Investment Management bought 6,602 Indivior Pharmaceuticals shares in Q2 2026, an estimated $239K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Zacks Investment Management's portfolio in Q2 2026, its #490 holding.
  • Zacks Investment Management first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.